Fulgent Genetics, Inc. FLGT
Fulgent Genetics, Inc. (Nasdaq: FLGT) is an oncology diagnostics company. Its next catalyst on record is FID-007: Phase 3 trial start (head and neck cancer), subject to end-of-Phase 2 FDA meeting (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: FID-007 — Phase 3 trial start (head and neck cancer), subject to end-of-Phase 2 FDA meeting (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| FID-007 | recurrent or metastatic head and neck squamous cell carcinoma (with cetuximab) | unclear | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Delcath Systems, Inc. DCTH
- Unknown Unknown
- Faeth Therapeutics, Inc. FTH
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.